Lifecore Biomedical, Inc.
A maker of sterile injectable medicines and medical devices, Lifecore Biomedical is a contract manufacturer producing pharmaceutical-grade sodium hyaluronate—the gel-like substance naturally found in the human eye—used in cataract surgery, orthopedics, and wound care. It traces its roots to 1981 in Chaska, Minnesota, built around the tricky task of making this thick, viscous material, and adopted the name 'Lifecore' in the late 1980s. Its product helps surgeons keep the eye's shape during cataract removal.
Bought 292.7K
Granted 75.4K · Bought 1.46M
Granted 713.5K · Bought 17.0K
Granted 432.2K
Sold 1.49M
Granted 282.0K
Granted 85.0K
Granted 85.0K
Granted 85.0K
Granted 17.5K
Granted 39.6K
Granted 39.6K
Granted 70.0K
Granted 39.6K
Granted 70.0K
Granted 70.0K
Granted 70.0K
Granted 39.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Landes Joshua +7 co-filers10% owner · 2 transactions | — | 4.70Mas of Oct 2024 | — | 292.7K | — |
| Kiper Christopher S +6 co-filersDirector, 10% owner · 5 transactions | +51.8% | 4.51M | 75.4K | 1.46M | — |
| Josephs PaulChief Executive Officer, Director · 9 transactions | — | 592.9K | 713.5K | 17.0K | — |
| Lake Ryan DavidChief Financial Officer · 8 transactions | — | 336.7K | 432.2K | — | — |
| English Aron R. +4 co-filers10% owner · 10 transactions | — | 264.2Kas of May 2025 | — | — | 1.49M |
| Salus Thomas D.Chief Legal & Administration · 6 transactions | — | 246.3K | 282.0K | — | — |
| Obus NelsonDirector · 4 transactions | +107.4% | 164.1K | 85.0K | — | — |
| Houde Lovas KatrinaDirector · 4 transactions | +168.7% | 135.3K | 85.0K | — | — |
| Schechter JoshuaDirector · 4 transactions | +176.6% | 133.1K | 85.0K | — | — |
| Morberg John DChief Financial Officer · 2 transactions | +95.1% | 125.6Kas of Jan 2024 | 17.5K | — | — |
| Barbarosh Craig A.Director · 2 transactions | +81.5% | 88.1Kas of Jul 2024 | 39.6K | — | — |
| Edwards Jeffrey LDirector · 2 transactions | +98.6% | 79.7Kas of Jul 2024 | 39.6K | — | — |
| Antunes Humberto CalheirosDirector · 3 transactions | — | 73.0K | 70.0K | — | — |
| Diradoorian Raymond HDirector · 2 transactions | +130% | 70.0Kas of Jul 2024 | 39.6K | — | — |
| Aryeh JasonDirector · 3 transactions | — | 70.0K | 70.0K | — | — |
| Johnson Paul HaroldDirector · 3 transactions | — | 70.0K | 70.0K | — | — |
| Korenberg Matthew EDirector · 3 transactions | — | 70.0K | 70.0K | — | — |
| Calloway NathanielDirector · 3 transactions | +219.4% | 58.1Kas of Jul 2024 | 39.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +282.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.